Trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Updated phase 2 safety and efficacy results

被引：0
|
作者：
Seneviratne, Lasika C.
Harnden, Kathleen Kiernan
Blau, Sibel
Danso, Michael A.
Berz, David
Guaqueta, Delia Constanza
Schwerkoske, John F.
O'Shaughnessy, Joyce
Patt, Debra A.
Bardia, Aditya
McCann, Kelly Elizabeth
Beelen, Andrew Paul
Zhang, Jingshan
Yi, John S.
Hurvitz, Sara A.
Mardones, Mabel Alejandra
机构：
[1] Los Angeles Canc Network, Los Angeles, CA USA
[2] Inova Schar Canc Inst, Fairfax, VA USA
[3] Northwest Med Specialties, Puyallup, WA USA
[4] Virginia Oncol Associates, Norfolk, VA USA
[5] Virginia Oncol Associates, Virginia Beach, VA USA
[6] Valkyrie Clin Trials Inc, Los Angeles, CA USA
[7] Mem Reg Hosp, Hollywood, FL USA
[8] Minnesota Oncol Hematol PA, Woodbury, MN USA
[9] Texas Oncol, Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
[10] Texas Oncol, US Oncol Network, Austin, TX USA
[11] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol Oncol, Los Angeles, CA 90095 USA
[12] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA
[13] Beverly Hills Canc Care, Los Angeles, CA USA
[14] G1 Therapeut Inc, Res Triangle Pk, NC USA
[15] Univ Washington Sch Med, Seattle, WA USA
[16] Fred Hutchinson Canc Ctr, Seattle, WA USA
[17] Rocky Mt Canc Ctr, Sarah Cannon Res Inst, Denver, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1091
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Exposure-response analyses of sacituzumab govitecan (SG) efficacy and safety in patients (pts) with metastatic triple-negative breast cancer (mTNBC).
    Singh, Indrajeet
    Sathe, Abhishek G.
    Singh, Pratap
    Diderichsen, Paul M.
    Fauchet, Floris
    Maringwa, John
    Pierrillas, Philippe
    Phan, See-Chun
    Girish, Sandhya
    Othman, Ahmed A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Metastatic triple-negative Breast Cancer (mTNBC) First-in-class Therapy with Sacituzumab Govitecan
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (1-2) : 64 - 65
  • [3] Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
    Bardia, A.
    Hurvitz, S. A.
    Tolaney, S. M.
    Loirat, D.
    Punie, K.
    Oliveira, M.
    Brufsky, A.
    Sardesai, S. D.
    Kalinsky, K.
    Zelnak, A. B.
    Weaver, R.
    Traina, T.
    Dalenc, F.
    Aftimos, P.
    Lynce, F.
    Diab, S.
    Cortes, J.
    O'Shaughnessy, J.
    Dieras, V
    Ferrario, C.
    Schmid, P.
    Carey, L. A.
    Gianni, L.
    Piccart, M. J.
    Loibl, S.
    Goldenberg, D. M.
    Hong, Q.
    Olivo, M. S.
    Itri, L. M.
    Rugo, H. S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (16): : 1529 - 1541
  • [4] Metastatic triple-negative breast cancer (mTNBC) first-in-class therapy with sacituzumab govitecan
    Schoellmann, Claudia
    BREAST CARE, 2022, 17 (01)
  • [5] Pharmacokinetics (PK) of sacituzumab govitecan (SG) in patients (Pts) with metastatic triple-negative breast cancer (mTNBC) and other solid tumors
    Sathe, A. G.
    Singh, I.
    Singh, P.
    Diderichsen, P.
    Wang, X.
    Chang, P.
    Phan, S-C.
    Girish, S.
    Othman, A. A.
    ANNALS OF ONCOLOGY, 2022, 33 : S214 - S214
  • [6] Assessment of sacituzumab govitecan (SG) in Black patients (pts) from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC)
    Carey, Lisa A.
    Zelnak, Amelia
    Rugo, Hope S.
    Dalenc, Florence
    Nanda, Rita
    Danso, Michael
    Saghatchian, Mahasti
    Kalinsky, Kevin
    Firmin, Nelly
    Ruiz-Borrego, Manuel
    Favret, Anne
    Sun, Jun
    Schwartzberg, Lee
    Hilton, Christie
    Omene, Coral
    Young, Robyn
    Hurvitz, Sara A.
    Harting, Eliza
    Phan, See
    Bardia, Aditya
    CANCER RESEARCH, 2022, 82 (04)
  • [7] HEALTH UTILITIES ASSOCIATED WITH SACITUZUMAB GOVITECAN (SG) FOR TREATING UNRESECTABLE LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC)
    Benedict, A.
    Rakonczai, P.
    Lovato, E.
    Proskorovsky, I
    Xiao, Y.
    Hodgson, M.
    McConkey, D.
    Gharaibeh, M.
    VALUE IN HEALTH, 2022, 25 (12) : S82 - S82
  • [8] Health-related quality of life (HRQoL) in the ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)
    Loibl, S.
    Loirat, D.
    Tolaney, S. M.
    Punie, K.
    Oliveira, M.
    Rugo, H. S.
    Bardia, A.
    Hurvitz, S. A.
    Brufsky, A.
    Kalinsky, K.
    Cortes, J.
    O'Shaughnessy, J.
    Dieras, V. C.
    Carey, L. A.
    Gianni, L.
    Gharaibeh, M.
    Moore, L.
    Shi, L.
    Piccart, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S472 - S473
  • [9] Tackling metastatic triple-negative breast cancer with sacituzumab govitecan
    Schreiber, Anna R.
    Andress, Michelle
    Diamond, Jennifer R.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (12) : 1303 - 1311
  • [10] Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC).
    Carey, Lisa A.
    Loirat, Delphine
    Punie, Kevin
    Bardia, Aditya
    Dieras, Veronique
    Dalenc, Florence
    Diamond, Jennifer Robinson
    Fontaine, Christel
    Wang, Grace
    Rugo, Hope S.
    Hurvitz, Sara A.
    Kalinsky, Kevin
    O'Shaughnessy, Joyce
    Loibl, Sibylle
    Gianni, Luca
    Piccart-Gebhart, Martine J.
    Hong, Quan
    Olivo, Martin Sebastian
    Itri, Loretta
    Cortes, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345